Breaking News: Angle PLC to Showcase Exciting HER2 Findings at SABCS Conference!
WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM
Independent findings support ANGLE’s HER2 assay development programme
Potential for stratification of breast cancer patients for treatment with HER2 antibody drug conjugates
SURREY, UK / ACCESSWIRE / December 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of an independent study, reporting on a novel, Parsortix®-based human epidermal growth factor receptor 2 (HER2) workflow at the prominent San Antonio Breast Cancer Symposium being held from 10 to 13 December 2024. The findings, published by Weill Cornell Medicine, corroborate ANGLE’s own findings from its HER2 assay development programme, and provide a semi-automated solution which may help to accelerate adoption of CTC-based HER2 tests.
Angle PLC’s groundbreaking HER2 findings presented at the San Antonio Breast Cancer Symposium have created a buzz in the medical community. The innovative Parsortix®-based HER2 workflow developed by Weill Cornell Medicine has the potential to revolutionize the way breast cancer patients are stratified for treatment with HER2 antibody drug conjugates.
HER2, also known as human epidermal growth factor receptor 2, is a protein that can promote the growth of cancer cells. Testing for HER2 status is crucial in determining the appropriate treatment for breast cancer patients. Angle PLC’s research aims to improve the accuracy and efficiency of HER2 testing through their innovative liquid biopsy technologies.
The findings presented at the SABCS Conference provide strong support for ANGLE’s ongoing HER2 assay development programme. By leveraging the Parsortix® system, researchers have been able to develop a semi-automated solution for HER2 testing that may streamline the process and lead to more personalized treatment options for breast cancer patients.
This exciting development in the field of liquid biopsy technology has the potential to significantly impact the way breast cancer is diagnosed and treated. By improving the accuracy and efficiency of HER2 testing, researchers hope to better tailor treatment plans for patients, ultimately leading to improved outcomes and quality of life.
Impact on Individuals:
For individuals, the advancements in HER2 testing presented by Angle PLC at the SABCS Conference could mean more personalized treatment options for those diagnosed with breast cancer. By accurately stratifying patients for HER2 antibody drug conjugates, patients may have access to more effective treatments tailored to their specific cancer subtype.
Impact on the World:
On a global scale, the development of a semi-automated HER2 workflow using liquid biopsy technologies has the potential to revolutionize the standard of care for breast cancer patients worldwide. By accelerating the adoption of CTC-based HER2 tests, researchers aim to improve patient outcomes and reduce the burden of this devastating disease on healthcare systems globally.
Conclusion:
The presentation of groundbreaking HER2 findings by Angle PLC at the SABCS Conference marks a significant step forward in the field of liquid biopsy technology. By providing a more efficient and accurate solution for HER2 testing, researchers hope to improve treatment outcomes for breast cancer patients and usher in a new era of personalized medicine in oncology.
